首页> 外文期刊>Journal of clinical psychopharmacology >Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.
【24h】

Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.

机译:在现实生活中使用奥氮平治疗后患有严重精神障碍的患者的代谢异常的激素标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Dyslipidemia independent of body mass has previously been reported in humans after antipsychotic treatment. The present study investigated the levels of several metabolic regulatory hormones in psychiatric outpatients treated with different antipsychotics under real-life conditions. METHODS: The study included cross-sectional data from 234 subjects on stable monotherapy with any of the following: olanzapine (n = 72), any other antipsychotic (n = 80), or no medications (n = 82). Groups were well matched for sex, body mass index (BMI), ethnicity, and smoking. After adjustment for differences in age and illness duration, groups were compared for the insulin resistance index (homeostatic model assessment of insulin resistance) and fasting concentrations of glucose, lipids, insulin, sex hormone-binding globulin (SHBG), adiponectin, leptin, and cortisol. Correlations were examined between serum olanzapine and hormonal levels, and between leptin concentrations and BMI in both sexes. RESULTS: Significant intergroup differences in concentrations of insulin (P = 0.025), SHBG (P = 0.001), adiponectin (P = 0.017), and cortisol (P = 0.003) but no significant difference for homeostatic model assessment of insulin resistance (P = 0.051) were found, independent of body mass. Olanzapine-treated subjects had the highest insulin concentrations and the lowest SHBG, adiponectin, and cortisol concentrations. Olanzapine-treated female subjects had significantly higher leptin (P = 0.005) and lower SHBG (P = 0.023) concentrations than other subjects. In female subjects, serum olanzapine concentrations were correlated with hormonal levels, and a significant proportion of olanzapine-treated female subjects had abnormal correlations between serum leptin levels and BMI. CONCLUSIONS: Alterations in several interrelated metabolic hormonal markers were associated with olanzapine treatment, independent of body mass, particularly in female subjects.
机译:目的:先前已报道抗精神病药物治疗后的人体血脂异常与体重无关。本研究调查了在现实生活中使用不同抗精神病药治疗的精神科门诊患者中几种代谢调节激素的水平。方法:该研究包括来自234名受试者的横断面数据,这些受试者采用以下任意一项进行稳定的单药治疗:奥氮平(n = 72),任何其他抗精神病药(n = 80)或没有药物(n = 82)。性别,体重指数(BMI),种族和吸烟的人群匹配良好。调整年龄和疾病持续时间的差异后,比较各组的胰岛素抵抗指数(胰岛素抵抗的稳态模型评估)和空腹血糖,脂质,胰岛素,性激素结合球蛋白(SHBG),脂联素,瘦素和皮质醇。检查了血清奥氮平与激素水平之间的相关性,以及两性之间的瘦素浓度与BMI之间的相关性。结果:胰岛素浓度(P = 0.025),SHBG(P = 0.001),脂联素(P = 0.017)和皮质醇(P = 0.003)的组间存在显着差异,但对胰岛素抵抗的稳态模型评估无显着差异(P = 0.051),与体重无关。奥氮平治疗的受试者的胰岛素浓度最高,SHBG,脂联素和皮质醇的浓度最低。与其他受试者相比,用奥氮平治疗的女性受试者的瘦素(P = 0.005)和SHBG(P = 0.023)的浓度明显更高。在女性受试者中,血清奥氮平浓度与激素水平相关,并且经奥氮平治疗的女性受试者中有很大比例的血清瘦素水平与BMI相关。结论:奥氮平治疗与多种相互关联的代谢激素标志物的改变有关,与体重无关,特别是在女性受试者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号